Have you evaluated the performance of Steris' (STE Quick QuoteSTE - Free Report) international operations during the quarter that concluded in March 2025? Considering the extensive worldwide presence of this medical products maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.

In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For investors, understanding a company's reliance on overseas markets has become increasingly crucial, as it offers insights into the company's sustainability of earnings, ability to tap into diverse economic cycles and overall growth potential.

Being present in foreign markets serves as protection against local economic declines and helps benefit from more rapidly expanding economies. Yet, such expansion also introduces challenges related to currency fluctuations, geopolitical uncertainties and varied market behaviors.

Our review of STE's last quarterly performance uncovered some notable trends in the revenue contributions from its international markets, which are commonly analyzed and tracked by Wall Street experts.

The company's total revenue for the quarter amounted to $1.48 billion, marking an increase of 4.3% from the year-ago quarter. We will next turn our attention to dissecting STE's international revenue to get a clearer picture of how significant its operations are outside its main base.

A Closer Look at STE's Revenue Streams Abroad

During the quarter, Ireland contributed $38.21 million in revenue, making up 2.58% of the total revenue. When compared to the consensus estimate of $25.51 million, this meant a surprise of +49.78%. Looking back, Ireland contributed $24.12 million, or 1.76%, in the previous quarter, and $22.66 million, or 1.60%, in the same quarter of the previous year.

Of the total revenue, $363.71 million came from Other Foreign Revenues during the last fiscal quarter, accounting for 24.57%. This represented a surprise of -12.43% as analysts had expected the region to contribute $415.31 million to the total revenue. In comparison, the region contributed $343.87 million, or 25.09%, and $360.69 million, or 25.41%, to total revenue in the previous and year-ago quarters, respectively.

Revenue Forecasts for the International Markets

It is projected by analysts on Wall Street that Steris will post revenues of $1.36 billion for the ongoing fiscal quarter, an increase of 6.1% from the year-ago quarter. The expected contributions from Ireland and Other Foreign Revenues to this revenue are 1.8% and 26.8%, translating into $23.87 million and $363.25 million, respectively.

For the full year, the company is projected to achieve a total revenue of $5.79 billion, which signifies a rise of 6% from the last year. The share of this revenue from various regions is expected to be: Ireland at 2.1% ($121.63 million) and Other Foreign Revenues at 27.4% ($1.58 billion).

In Conclusion

Relying on global markets for revenues presents both prospects and challenges for Steris. Therefore, scrutinizing its international revenue trends is key to effectively forecasting the company's future outlook.

In an environment where global interconnections and geopolitical skirmishes are intensifying, Wall Street analysts keep a keen eye on these trends, particularly for firms with overseas operations, to adjust their earnings predictions. Moreover, a range of other aspects, including how a company fares in its home country, significantly affects these projections.

Emphasizing a company's shifting earnings prospects is a key aspect of our approach at Zacks, especially since research has proven its substantial influence on a stock's price in the short run. This correlation is positively aligned, meaning that improved earnings projections tend to boost the stock's price.

The Zacks Rank, our proprietary stock rating tool, comes with an externally validated impressive track record. It effectively utilizes shifts in earnings projections to act as a dependable barometer for forecasting short-term stock price trends.

Steris, bearing a Zacks Rank #2 (Buy), is expected to outperform the broader market's movements in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

A Review of Steris' Recent Stock Market Performance

The stock has increased by 13.2% over the past month compared to the 13.1% rise of the Zacks S&P 500 composite. Meanwhile, the Zacks Medical sector, which includes Steris, has increased 0.1% during this time frame. Over the past three months, the company's shares have experienced a gain of 14.1% relative to the S&P 500's 2.3% decline. Throughout this period, the sector overall has witnessed a 9.5% decrease.